Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CPRX Catalyst Pharmaceutical Partners

盘后交易 06-17 19:43:20 EDT

31.40

+0.05

+0.16%

盘后31.22

-0.18-0.57%

19:40 EDT

最高31.40	最低31.35	成交量286.85万
今开31.35	昨收31.35	日振幅0.16%
总市值38.35亿	流通市值36.12亿	总股本1.22亿
成交额9,000万	换手率2.49%	流通股本1.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CPRX","market":"US","secType":"STK","nameCN":"Catalyst Pharmaceutical Partners","latestPrice":31.4,"timestamp":1781726400000,"preClose":31.35,"halted":0,"volume":2868492,"hourTrading":{"tag":"盘后","latestPrice":31.22,"preClose":31.4,"latestTime":"19:40 EDT","volume":49741,"amount":1561769.211266,"timestamp":1781739643007,"change":-0.18,"changeRate":-0.005732,"amplitude":0.005732},"delay":0,"changeRate":0.0015948963317383464,"floatShares":115016976,"shares":122123884,"eps":1.729853,"marketStatus":"盘后交易","change":0.05,"latestTime":"06-17 19:43:20 EDT","open":31.35,"high":31.4,"low":31.35,"amount":89999082.793092,"amplitude":0.001595,"askPrice":31.5,"askSize":40,"bidPrice":31.22,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.729853,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781740800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1162962000000,"exchange":"NASDAQ","adjPreClose":31.35,"preHourTrading":{"tag":"盘前","latestPrice":31.35,"preClose":31.35,"latestTime":"09:27 EDT","volume":1608,"amount":50405.684952,"timestamp":1781702860336,"change":0,"changeRate":0,"amplitude":0.00925},"postHourTrading":{"tag":"盘后","latestPrice":31.22,"preClose":31.4,"latestTime":"19:40 EDT","volume":49741,"amount":1561769.211266,"timestamp":1781739643007,"change":-0.18,"changeRate":-0.005732,"amplitude":0.005732},"volumeRatio":1.921586,"impliedVol":0.1739,"impliedVolPercentile":0.1076},"requestUrl":"/m/hq/s/CPRX","defaultTab":"news","newsList":[{"id":"1193535006","title":"花旗集团下调Catalyst Pharmaceuticals评级至中性，目标价降至31.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193535006","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193535006?lang=zh_cn&edition=full","pubTime":"2026-05-11 18:34","pubTimestamp":1778495651,"startTime":"0","endTime":"0","summary":"花旗集团调整了对Catalyst Pharmaceuticals Inc.的投资评级，将其从“买入”下调至“中性”。同时，该机构亦将其目标股价从之前的35美元调降至31.50美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX","BK4139","IE0034390439.USD","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114908790","title":"并购协议终止触发条款 Catalyst制药需向Angelini支付约1.555亿美元解约金","url":"https://stock-news.laohu8.com/highlight/detail?id=1114908790","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114908790?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:51","pubTimestamp":1778158278,"startTime":"0","endTime":"0","summary":"根据并购协议中的特别约定，若交易最终未能完成，Catalyst Pharmaceuticals将面临重大财务支出。最新披露的条款显示，一旦协议终止，该公司必须向合作方Angelini Pharma支付高达约1.555亿美元的终止费用。这项条款的触发条件与协议中规定的特定情形直接关联。对于Catalyst Pharmaceuticals而言，这笔潜在支出将对其现金流和财务状况产生显著影响。投资者需密切关注事件后续发展，特别是协议终止的具体原因及公司应对策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034390439.USD","IE00B19Z6F94.USD","CPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141130765","title":"安杰利尼制药斥资41亿美元收购Catalyst制药公司 强势进军美国市场并巩固脑健康与罕见病领域领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1141130765","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141130765?lang=zh_cn&edition=full","pubTime":"2026-05-07 14:16","pubTimestamp":1778134610,"startTime":"0","endTime":"0","summary":"意大利制药巨头安杰利尼制药公司宣布将以41亿美元的全现金交易收购美国生物制药企业Catalyst Pharmaceuticals。这笔重磅交易标志着安杰利尼正式进军全球最大的医药市场，并将显著增强其在神经科学和罕见病治疗领域的全球布局。通过此次战略收购，安杰利尼将获得Catalyst制药公司已商业化的罕见病治疗产品组合，特别是其在神经肌肉疾病领域的专长。此次收购将进一步巩固安杰利尼在专科治疗领域的领导地位，为其长期增长注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPRX","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172368880","title":"Catalyst Pharmaceuticals携手黑石基金及国际合作伙伴达成重大交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1172368880","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172368880?lang=zh_cn&edition=full","pubTime":"2026-05-07 14:16","pubTimestamp":1778134571,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals近日宣布，将联合黑石集团旗下基金及精选国际合作伙伴共同推进一项战略合作。此次多方参与的商业布局标志着公司在全球资源整合方面迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","BK4588","BK4585","IE00B19Z6F94.USD","IE00BN8TJ469.HKD","IE0004445239.USD","IE00BGHQF748.EUR","IE00BLSP4452.SGD","BK4135","IE0034390439.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BX","CPRX","BK4139","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178562411","title":"财报前瞻｜Catalyst Pharmaceutical Partners本季度营收预计小幅增长，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1178562411","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178562411?lang=zh_cn&edition=full","pubTime":"2026-05-04 08:56","pubTimestamp":1777856188,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners将于2026年05月11日发布最新季度财报，市场预期本季度营收与利润温和增长，核心产品稳定推动业绩表现。市场一致预期本季度Catalyst Pharmaceutical Partners收入为1.48亿美元，同比增长12.67%，EPS为0.44美元，同比增长28.68%，EBIT为6,758.14万美元，同比增长25.28%；公司上季度财报中未披露针对本季度的明确收入或利润指引，公开预测口径以卖方一致预期为主。卖方研究对Catalyst Pharmaceutical Partners的短期前景整体偏积极。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Catalyst Pharmaceutical Partners本季度营收预计小幅增长，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197246536","title":"财报前瞻｜Catalyst Pharmaceutical Partners营收或增5.84%，机构偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1197246536","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197246536?lang=zh_cn&edition=full","pubTime":"2026-02-18 12:29","pubTimestamp":1771388940,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners将于2026年02月25日发布最新季度财报，市场关注营收与盈利的韧性及指引变化。一致预期显示，本季度Catalyst Pharmaceutical Partners营收约为1.42亿USD，同比增5.84%；调整后每股收益约为0.34美元，同比降0.76%；息税前利润约为5,186.28万USD，同比降3.13%，目前市场未披露本季度毛利率与净利率的预测，净利润的一致预期亦暂缺。上季度Catalyst Pharmaceutical Partners营收为1.48亿USD，同比增长15.31%；毛利率为82.94%；归属母公司净利润为5,278.30万USD，净利率为35.57%；调整后每股收益为0.42美元，同比增长20.00%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Catalyst Pharmaceutical Partners营收或增5.84%，机构偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518273726","title":"Catalyst Pharmaceuticals, Inc.盘中异动 早盘急速下挫5.10%报20.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518273726?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:04","pubTimestamp":1741615445,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时04分，Catalyst Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.10%。截至发稿，该股报20.84美元/股，成交量14.9957万股，换手率0.12%，振幅3.57%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为675.90%、345.51%、94.18%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Pmgc Holdings Inc.，振幅分别为41.36%、40.24%、32.14%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022040598a2a59c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022040598a2a59c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CPRX","IE0034390439.USD","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516633545","title":"Baird：维持Catalyst Pharmaceuticals(CPRX.US)评级，由优于大市调整至优于大市评级, 目标价由28.00美元调整至32.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633545","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516633545?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:51","pubTimestamp":1741006290,"startTime":"0","endTime":"0","summary":"Baird：维持Catalyst Pharmaceuticals(CPRX.US)评级，由优于大市调整至优于大市评级, 目标价由28.00美元调整至32.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03205148492764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516548200","title":"Catalyst Pharmaceuticals, Inc.2024财年实现净利润1.64亿美元，同比增加129.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516548200?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931292,"startTime":"0","endTime":"0","summary":"3月3日，Catalyst Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为1.64亿美元，同比增加129.66%；其中营业收入为4.92亿美元，同比增加23.62%，每股基本收益为1.38美元。从资产负债表来看，Catalyst Pharmaceuticals, Inc.总负债1.27亿美元，其中短期债务402000.00美元，资产负债比为6.73，流动比率为5.16。机构评级：截至2025年3月3日，当前有8家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测，其中目标均价为33.12美元，其中最低目标价为28.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000232abe4acfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000232abe4acfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127825978","title":"异动解读 | Catalyst Pharmaceutical Partners(CPRX)盘中大涨5.08%，盘面活跃受追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1127825978","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127825978?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:44","pubTimestamp":1740775472,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners(CPRX)今日盘中大涨5.08%，引发市场关注。\n\n消息面上，CPRX最新的财报数据显示，公司实现营业收入4.92亿美元，净利润1.64亿美元，盈利能力强劲，每股收益1.38美元。此外，机构方面给予100%买入评级，看好公司长期发展前景。\n\n盘面上，CPRX今日盘中成交活跃，成交量达92.6048万股，换手率0.76%，振幅达4.85%。公司在生物技术行业内获追捧，整个板块也出现不错的上涨表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Catalyst Pharmaceutical Partners(CPRX)盘中大涨5.08%，盘面活跃受追捧","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516730955","title":"Catalyst Pharmaceuticals, Inc.盘中异动 急速拉升5.03%报22.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516730955","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516730955?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:42","pubTimestamp":1740775320,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时42分，Catalyst Pharmaceuticals, Inc.股票出现异动，股价急速拉升5.03%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.73%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Camp4 Therapeutics Corporation、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3281.85%、605.06%、401.08%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、49.90%、48.19%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030104420096346500&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030104420096346500&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CPRX","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122460757","title":"异动解读 | Catalyst Pharmaceutical Partners公布亮眼业绩报告,股价盘中大涨10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1122460757","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122460757?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:46","pubTimestamp":1740667600,"startTime":"0","endTime":"0","summary":"周四盘中交易期间,Catalyst Pharmaceutical Partners股价出现了大幅上涨,截至上午9:32,股价累计上涨10.84%,引发了市场的广泛关注。此前公司周三晚间公布的2024年第四季度业绩报告成为本轮上涨行情的主要推手。财报显示,Catalyst Pharmaceutical Partners当季每股收益0.70美元,远高于分析师平均预期的0.34美元。作为Catalyst Pharmaceutical Partners的核心产品,旗舰药品在过去一个季度保持了优异的销售业绩,为公司带来了强劲的营收增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385851","title":"Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨8.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385851","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385851?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:30","pubTimestamp":1740666645,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时30分，Catalyst Pharmaceuticals, Inc.股票出现波动，股价急速上涨8.45%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Quoin Pharmaceuticals Ltd、Pasithea Therapeutics Corp C/Wts 12/08/2026 、天演药业涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为391.76%、89.32%、48.01%，振幅较大的相关个股有天演药业、内克塔治疗、Scorpius Holdings, Inc.，振幅分别为10.10%、7.64%、6.33%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223045abdf6e2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223045abdf6e2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX","IE00B19Z6F94.USD","IE0034390439.USD","BK4139","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164666029","title":"异动解读 | Catalyst Pharmaceutical Partners公布亮眼财报,股价盘前大涨8.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164666029","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164666029?lang=zh_cn&edition=full","pubTime":"2025-02-27 21:03","pubTimestamp":1740661408,"startTime":"0","endTime":"0","summary":"周四盘前交易中,Catalyst Pharmaceutical Partners股价大涨8.6%,引发了市场的广泛关注。数据显示,该股开盘参考价为15.35美元,较上一交易日收盘价上涨幅度达到8.6%。导致该股价大涨的主要原因是,该公司于周三晚间发布了2024年第四季度财报,营收和利润数据双双超出市场预期。Catalyst Pharmaceutical Partners的优异财报成绩主要源自公司旗舰产品在市场保持良好的销售势头,增强了投资者对该公司长期发展前景的信心,从而推动该公司在盘前交易中股价出现大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187017244","title":"异动解读 | Catalyst Pharmaceutical Partners盘后大涨8.36%,财报数据超预期成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1187017244","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187017244?lang=zh_cn&edition=full","pubTime":"2025-02-27 09:18","pubTimestamp":1740619129,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners(纳斯达克代码:CPRX)周三夜盘大涨8.36%,引发了市场广泛关注。\n\n导致该股盘后大涨的主要原因是,公司新发布的2024年第四季度财报数据超出市场预期。财报显示,公司第四季度每股收益为0.70美元,高于分析师一致预期的0.34美元,同比增长32.08%;营收方面实现14.181亿美元,也超出预期的13.42亿美元,同比增长28.26%。\n\n优异的业绩表现体现了公司产品在市场的良好销售势头,增强了投资者对其长期发展前景的信心,从而推动公司盘后股价出现大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164497473","title":"异动解读 | Catalyst Pharmaceutical Partners盘后大涨8.14% 财报数据超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1164497473","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164497473?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:46","pubTimestamp":1740606396,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners(CPRX)今日盘后大涨8.14%,引发市场高度关注。这主要归功于其刚公布的2024年第四季度财报数据实现大超预期。\n\n财报显示,公司本季度每股收益为0.70美元,高于分析师一致预期的0.34美元,同比增长32.08%。营收方面,公司本季度实现14.181亿美元,也高于分析师预期的13.42亿美元,同比增长28.26%。\n\n优异的业绩表现体现了公司产品在市场的良好销售态势,这进一步增强了投资者对公司的信心,带动了其盘后股价的大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129283897","title":"药物催化剂公司2024年第四季度调整后每股收益$0.70 高于预期$0.34，销售额$1.4181亿 超过预期$1.342亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1129283897","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129283897?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:32","pubTimestamp":1740605558,"startTime":"0","endTime":"0","summary":"药物催化剂公司报告季度每股收益$0.70，比分析师一致预期的$0.34高出105.88%。这比去年同期的每股收益$0.53增长了32.08%。公司报告季度销售额为$1.4181亿，超过分析师一致预期的$1.342亿，高出5.67%。以上内容来自Benzinga Earnings专栏，原文如下：Catalyst Pharmaceuticals  reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.34 by 105.88 percent. This is a 32.08 percent increase over earnings of $0.53 per share from the same period last year.  The company reported quarterly sales of $141.81 million which beat the analyst consensus estimate of $134.20 mi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药物催化剂公司2024年第四季度调整后每股收益$0.70 高于预期$0.34，销售额$1.4181亿 超过预期$1.342亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502686500","title":"HC Wainwright & Co.：维持Catalyst Pharmaceuticals(CPRX.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至35.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2502686500","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502686500?lang=zh_cn&edition=full","pubTime":"2025-01-10 21:27","pubTimestamp":1736515664,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Catalyst Pharmaceuticals(CPRX.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至35.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/10212747358713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483383028","title":"Catalyst Pharmaceuticals, Inc.2024财年第三财季实现净利润43.88百万美元，同比增加242.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483383028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483383028?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:02","pubTimestamp":1731600145,"startTime":"0","endTime":"0","summary":"11月15日，Catalyst Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为43.88百万美元，同比增加242.65%；其中营业收入为1.29亿美元，同比增加25.24%，每股基本收益为0.37美元。从资产负债表来看，Catalyst Pharmaceuticals, Inc.总负债1.11亿美元，其中短期债务393000.00美元，资产负债比为6.96，流动比率为5.14。机构评级：截至2024年11月15日，当前有7家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测，其中目标均价为31.86美元，其中最低目标价为28.00美元，最高目标价为38.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000303a23801c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000303a23801c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129925010","title":"异动解读 | 催化剂公司财报利好推动股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1129925010","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129925010?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:46","pubTimestamp":1731033995,"startTime":"0","endTime":"0","summary":"专注罕见病药物研发的催化剂制药公司股价今日盘前大涨6.78%,最高触及18.4美元,引发市场关注。公司上周公布的最新季度业绩显着超预期成为主要推手。财报数据显示,催化剂公司第三季度营收同比大增25.3%至1.287亿美元,高于分析师平均预期。同时归属普通股东的净利润达4388万美元,去年同期为亏损。受业绩超预期利好因素影响,华尔街分析师纷纷上调对该股的评级和目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.catalystpharma.com","stockEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.0055},{"period":"3month","weight":0.3744},{"period":"6month","weight":0.3245},{"period":"1year","weight":0.3245},{"period":"ytd","weight":0.3432}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Catalyst Pharmaceuticals, Inc.于2006年7月在特拉华州注册成立。该公司是一家商业阶段、以患者为中心的生物制药公司，专注于为患有罕见和难以治疗的疾病的患者提供新的高质量药物的许可、开发和商业化。该公司利用协调一致的勤奋努力，寻找能够改善那些患有罕见或难以治疗的疾病的人的生活的疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.054585},{"month":2,"riseRate":0.65,"avgChangeRate":-0.012753},{"month":3,"riseRate":0.7,"avgChangeRate":0.100484},{"month":4,"riseRate":0.45,"avgChangeRate":0.039847},{"month":5,"riseRate":0.6,"avgChangeRate":-0.02255},{"month":6,"riseRate":0.55,"avgChangeRate":0.036646},{"month":7,"riseRate":0.578947,"avgChangeRate":0.111528},{"month":8,"riseRate":0.631579,"avgChangeRate":0.2208},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.027783},{"month":10,"riseRate":0.473684,"avgChangeRate":-0.048724},{"month":11,"riseRate":0.578947,"avgChangeRate":0.015249},{"month":12,"riseRate":0.3,"avgChangeRate":-0.029987}],"exchange":"NASDAQ","name":"Catalyst Pharmaceutical Partners","nameEN":"Catalyst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Catalyst Pharmaceutical Partners,CPRX,Catalyst Pharmaceutical Partners股票,Catalyst Pharmaceutical Partners股票老虎,Catalyst Pharmaceutical Partners股票老虎国际,Catalyst Pharmaceutical Partners行情,Catalyst Pharmaceutical Partners股票行情,Catalyst Pharmaceutical Partners股价,Catalyst Pharmaceutical Partners股市,Catalyst Pharmaceutical Partners股票价格,Catalyst Pharmaceutical Partners股票交易,Catalyst Pharmaceutical Partners股票购买,Catalyst Pharmaceutical Partners股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}